Development of Diagnostic Reagents Detecting Cancer Specific Proteins for Cancer Screening

When cancers begin, until the time when they cause the death of the persons with them, they develop by stages over many years. This process of development, when uninterrupted by treatment, is the natural process of cancer. The increasing knowledge of the natural history of cancer and the specific characteristics of its stages are leading to the development of new and more specific ways of preventing and managing cancers. A variety of screening strategies have been proposed in an attempt to interrupt the natural history of cancer through detecting an early stage, asymptomatic tumors. In previous studies, we have found a potential biomarker, STOML2, peculiarly expressed on colorectal cancer and detected in plasma samples from patients with CRC. Stomatin-like protein 2 ( STOML2 ) can contribute to the promotion of cell growth, cell adhesion, and tumorigenesis and widely express in many canceer including esophageal squamous cell carcinoma ( ESCC ), lung cancer, breast cancer and lymph node metastasis in laryngeal squamous cell carcinoma ( LSCC ). In this project, we will construct an immunoassay to detect STOML2 in clinical screening of patient’s serum. The immunoassay utilizes an enzyme-linked immunosorbent assay (ELISA) technology combining an anti-STOML2 monoclonal antibody with an polyclonal antibody. Plasma and serum samples of patients with colorectal, lung and breast cancer were analysed with STOML2 expression. The assay could detect the specific antigen from cancer patient serum and might contribute a clinically useful non-invasive approach to cancer detection and diagnosis.

Project ID:PC10006-0030
External Project ID:NSC100-2622-B182-001-CC3